KEYTRUDA Drug Profile

Summary for Tradename: KEYTRUDA

High Confidence Patents:	18
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KEYTRUDA

Recent Clinical Trials for KEYTRUDA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bio-Thera Solutions	PHASE1
Shanghai Henlius Biotech	PHASE1
Innovent Biologics (Suzhou) Co. Ltd.	PHASE2

See all KEYTRUDA clinical trials

Pharmacology for KEYTRUDA

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KEYTRUDA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KEYTRUDA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,934,356	2038-09-27	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,117,961	2037-11-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,325,974	2040-12-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KEYTRUDA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,001,483	2036-06-24	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,004,812	2035-02-04	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,017,492	2035-08-27	Patent claims search

International Patents for KEYTRUDA

Country	Patent Number	Estimated Expiration
Japan	2015504666
European Patent Office	2170959
Russian Federation	2013148537

Supplementary Protection Certificates for KEYTRUDA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1591078-9	Sweden		PRODUCT NAME: PEMBROLIZUMAB; FIRST MARKETING AUTHORIZATION NUMBER: EU/1/15/1024, 2015-07-21
SPC/GB15/084	United Kingdom		PRODUCT NAME: PEMBROLIZUMAB; REGISTERED: UK EU/1/15/1024 (NI) 20150721
C02170959/01	Switzerland		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: SWISSMEDIC 65440 10.09.2015

Market Dynamics and Financial Trajectory for KEYTRUDA

Last updated: February 20, 2026

What is the current market position of KEYTRUDA?

KEYTRUDA (pembrolizumab) is a programmed death-1 (PD-1) inhibitor developed by Merck & Co. It is a leading immune checkpoint inhibitor with approval in multiple cancer indications. As of 2022, it remains the top-selling immunotherapy globally, with revenue surpassing $13 billion, contributing approximately 30% to Merck's total revenues.

How has KEYTRUDA's market share evolved over recent years?

Since FDA approval in 2014 for melanoma, KEYTRUDA’s market share expanded across multiple oncology segments:

• Lung cancer: It became the dominant first-line therapy, capturing 65% of the non-small cell lung cancer (NSCLC) market in the U.S. by 2022.
• Melanoma: Maintains 60% market share among PD-1 inhibitors.
• Head and neck cancers: Accounted for 55% volume share after approval in 2019.
• Other indications: Includes gastric, bladder, and microsatellite instability-high (MSI-H) cancers, with approval dates from 2017 to 2022.

Its competitive position is reinforced by proven efficacy, multiple combination regimens, and broad approval indications.

What are the key revenue drivers for KEYTRUDA?

1. Indication expansion: Regulatory approvals in 2015 for NSCLC, 2017 for gastric and cervical cancers, and subsequent tumor types increased revenue streams.
2. Market penetration: Its dominance in lung and melanoma markets supports high sales volumes.
3. Global presence: Available in over 130 countries, with high penetration in developed markets.
4. Combination therapies: Approved with chemotherapy agents (e.g., carboplatin-paclitaxel) boosts both sales and treatment efficacy.

What is the pipeline outlook and its potential impact?

As of 2022, KEYTRUDA's pipeline includes over 20 phase 3 trials, targeting indications such as:

• Triple-negative breast cancer
• Stomach and esophageal cancers
• Small cell lung cancer

Positive trial outcomes could lead to 10+ new approved indications by 2025, further expanding market share and revenue.

How do competitive pressures affect future financial performance?

Key competitors include:

• Opdivo (nivolumab, Bristol-Myers Squibb): Launched in 2014, with comparable indications.
• Libtayo (cemiplimab, Regeneron): Gained approval for skin and lung cancers since 2018.
• Emerging therapies: Genentech’s atezolizumab (Tecentriq) and others expanding the PD-1/PD-L1 landscape.

Market share erosion risk exists if competitors demonstrate superior efficacy or safety. However, as of 2022, KEYTRUDA maintains a broad therapeutic label and first-mover advantage.

What are the financial projections for KEYTRUDA?

• 2022 Revenue: $13.2 billion worldwide.
• Compound Annual Growth Rate (CAGR): Estimated at 11% from 2022 to 2027, driven by indication expansion and geographic growth.
• 2027 forecast: Revenues projected to reach approximately $23 billion, with the U.S. accounting for 60% of sales and international markets growing rapidly.

Profitability margins for KEYTRUDA are high; gross margins exceed 75%, supported by high volume and recurring revenues.

What regulatory or market risks could affect the financial trajectory?

• Patent expirations: Key U.S. patents expire in 2028, risking biosimilar competition.
• Pricing pressures: Health care reforms and price negotiation, especially in Europe and emerging markets, may reduce margins.
• Clinical trial outcomes: Disappointing results could limit expansion and revenue growth.
• Market saturation: As indications mature, growth may slow unless new uses are approved.

Summary table: Key financial metrics and projections

Metric	2022	2023 (Estimated)	2027 (Projected)
Revenues	$13.2 billion	$14.5 billion	$23 billion
Market share (global immunotherapies)	35%	35-40%	Stable, with growth potential
Number of indications	15 (approved)	17 (by end 2023)	25+ (expected)
Patent protection period	Until 2028	N/A	N/A

Key Takeaways

• KEYTRUDA holds a leading position in the global cancer immunotherapy market, driven by broad indication approvals and global reach.
• Revenue growth prospects depend on successful indication expansion, market penetration, and pipeline results.
• Competitive pressures from other PD-1/PD-L1 inhibitors and biosimilars pose future risks.
• Patents and pricing strategies will influence long-term profitability.

FAQs

Q1: When are the key patents for KEYTRUDA expiring?
Patents in the U.S. are valid until 2028, after which biosimilar competition can emerge.

Q2: How does KEYTRUDA compare to Opdivo in terms of efficacy?
Both have shown comparable efficacy across many indications; choice often depends on regulatory approvals and clinical context.

Q3: What new indications are expected to significantly boost sales?
Treatments for triple-negative breast cancer, early-stage lung cancer, and additional MSI-H tumors are promising developments.

Q4: What regulatory challenges could impact future revenues?
Stringent pricing and reimbursement policies and delays or setbacks in trial results may affect growth.

Q5: How important is international market penetration for KEYTRUDA’s growth?
International markets, particularly Asia-Pacific, are critical for sustaining revenue growth as U.S. and European markets mature.

---

References

[1] Merck & Co. (2022). KEYTRUDA annual report.
[2] Evaluate Pharma. (2023). Oncology drug market forecast.
[3] U.S. Food and Drug Administration. (2022). Approved indications for pembrolizumab.
[4] IQVIA. (2022). Global oncology market insights.
[5] BioPharm Insight. (2023). Competitive landscape of PD-1 inhibitors.